Bronchial asthma
Conditions
Interventions
Patients whose asthma was controlled with salmeterol/fluticasone(low or moderate dose) for at least 3 months,are switched to step-down treatment with ciclesonide and tulobuterol patch. If the asthma i
Sponsors
Hiroshima Allergy Research Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: In patients with bronchial asthma (or cough variant asthma), all of the following criteria was required for enrollment : 1) age;20 years or more 2) receiving low or medium dose salmeterol/fluticasone propionate diskus for at least 3 months, and ACT total score =20 or >20 at baseline 3) no use of oral corticosteroids or systemic rescue medication within previous 3 months 4) little or nothing of asthma symptoms within previous 3 months 5) use of 2 times or less per 2 weeks of short-acting beta2-agonist within previous 1 month 6) Written informed consent from the patients
Exclusion criteria
Exclusion criteria: 1)addition or dose-change of antiasthma medications (except for salmeterol/fluticasone propionate diskus) within previous 3 months 2)use of ciclesonide and beta2-agonist tulobuterol patch within previous 3 months 3)corresponding to contraindication on accompanied note of study medication 4)difficult to answer of self administered questionnaire 5)physician decided the patient is unsuitable to enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| percentage of patients with reducing treatment and maintaining control of asthma | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)pulmonary function using spirometry 2)questionnaire of asthma control 3)questionnaire of adverse effects 4)impulse oscillation system parameters and exhaled nitric oxide (only 2 ceters) 5)adverse events | — |
Countries
Japan
Contacts
Public ContactShintaro Miyamoto
Hiroshima University Hospital Department of respiratory medicine
Outcome results
None listed